Nurix Therapeutics Outlines 2024 Strategic Priorities with Advancement of Targeted Protein Modulation Pipeline in Cancer and Autoimmune Diseases Portfolio News / By Karina Tin January 8, 2024 Nurix Therapeutics Outlines 2024 Strategic Priorities with Advancement of Targeted Protein Modulation Pipeline in Cancer and Autoimmune Diseases Read More »
Remix Therapeutics™ Closes $60 Million Financing to Advance REM-422, Pipeline of Small Molecule Therapies Designed to Reprogram RNA Processing to Treat Disease Portfolio News / By Karina Tin January 3, 2024 Remix Therapeutics™ Closes $60 Million Financing to Advance REM-422, Pipeline of Small Molecule Therapies Designed to Reprogram RNA Processing to Treat Disease Read More »
Remix Therapeutics™ Enters Collaboration with Roche for the Discovery and Development of Small Molecule Therapeutics Modulating RNA Processing Portfolio News / By Karina Tin January 3, 2024 Remix Therapeutics™ Enters Collaboration with Roche for the Discovery and Development of Small Molecule Therapeutics Modulating RNA Processing Read More »
Kimia Therapeutics Raises $55 Million Series A Portfolio News / By Karina Tin December 19, 2023 Kimia Therapeutics Raises $55 Million Series A Read More »
Atavistik Bio Raises Additional $40 Million to Advance Precision Allosteric Small Molecule Therapeutics Portfolio News / By Karina Tin December 19, 2023 Atavistik Bio Raises Additional $40 Million to Advance Precision Allosteric Small Molecule Therapeutics Read More »
Nurix Therapeutics Presents Positive Clinical Data from Its Novel Bruton’s Tyrosine Kinase (BTK) Degrader Programs, NX-5948 and NX-2127, at the 65th American Society of Hematology (ASH) Annual Meeting Portfolio News / By Karina Tin December 11, 2023 Nurix Therapeutics Presents Positive Clinical Data from Its Novel Bruton’s Tyrosine Kinase (BTK) Degrader Programs, NX-5948 and NX-2127, at the 65th American Society of Hematology (ASH) Annual Meeting Read More »
Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination Development Portfolio News / By Karina Tin December 11, 2023 Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination Development Read More »
Plexium Initiates Dosing in Phase 1 Study of PLX-4545, a Potent and Selective Degrader of the Transcription Factor IKZF2 Portfolio News / By Karina Tin December 11, 2023 Plexium Initiates Dosing in Phase 1 Study of PLX-4545, a Potent and Selective Degrader of the Transcription Factor IKZF2 Read More »
Carmot Therapeutics Enters into Definitive Merger Agreement with Roche Portfolio News / By Karina Tin December 4, 2023 Carmot Therapeutics Enters into Definitive Merger Agreement with Roche Read More »
Neurona Therapeutics Presents New Clinical Data from First Cohort in Ongoing Phase I/II Open-Label Trial of NRTX-1001 Cell Therapy for Drug-resistant Mesial Temporal Lobe Epilepsy (MTLE) Portfolio News / By Karina Tin December 1, 2023 Neurona Therapeutics Presents New Clinical Data from First Cohort in Ongoing Phase I/II Open-Label Trial of NRTX-1001 Cell Therapy for Drug-resistant Mesial Temporal Lobe Epilepsy (MTLE) Read More »
